These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33552852)

  • 1. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis.
    Mpekris F; Panagi M; Voutouri C; Martin JD; Samuel R; Takahashi S; Gotohda N; Suzuki T; Papageorgis P; Demetriou P; Pierides C; Koumas L; Costeas P; Kojima M; Ishii G; Constantinidou A; Kataoka K; Cabral H; Stylianopoulos T
    Adv Sci (Weinh); 2021 Feb; 8(3):2001917. PubMed ID: 33552852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas.
    Mpekris F; Panagi M; Charalambous A; Voutouri C; Michael C; Papoui A; Stylianopoulos T
    Neoplasia; 2024 May; 51():100990. PubMed ID: 38520790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.
    Mpekris F; Voutouri C; Panagi M; Baish JW; Jain RK; Stylianopoulos T
    J Control Release; 2022 May; 345():190-199. PubMed ID: 35271911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models.
    Mpekris F; Papaphilippou PC; Panagi M; Voutouri C; Michael C; Charalambous A; Marinov Dinev M; Katsioloudi A; Prokopi-Demetriades M; Anayiotos A; Cabral H; Krasia-Christoforou T; Stylianopoulos T
    ACS Nano; 2023 Dec; 17(24):24654-24667. PubMed ID: 38054429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner.
    Papageorgis P; Polydorou C; Mpekris F; Voutouri C; Agathokleous E; Kapnissi-Christodoulou CP; Stylianopoulos T
    Sci Rep; 2017 Apr; 7():46140. PubMed ID: 28393881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models.
    Panagi M; Mpekris F; Chen P; Voutouri C; Nakagawa Y; Martin JD; Hiroi T; Hashimoto H; Demetriou P; Pierides C; Samuel R; Stylianou A; Michael C; Fukushima S; Georgiou P; Papageorgis P; Papaphilippou PC; Koumas L; Costeas P; Ishii G; Kojima M; Kataoka K; Cabral H; Stylianopoulos T
    Nat Commun; 2022 Nov; 13(1):7165. PubMed ID: 36418896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy.
    Zheng X; Kuai J; Shen G
    Immunotherapy; 2023 Apr; 15(6):429-442. PubMed ID: 36880262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment.
    Mpekris F; Panagi M; Michael C; Voutouri C; Tsuchiya M; Wagatsuma C; Kinoh H; Osada A; Akinaga S; Yoshida S; Martin JD; Stylianopoulos T
    J Control Release; 2023 Jan; 353():956-964. PubMed ID: 36516902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer nanomedicine meets immunotherapy: opportunities and challenges.
    Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y
    Acta Pharmacol Sin; 2020 Jul; 41(7):954-958. PubMed ID: 32555445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bifunctional Therapeutic Peptide Assembled Nanoparticles Exerting Improved Activities of Tumor Vessel Normalization and Immune Checkpoint Inhibition.
    Taleb M; Atabakhshi-Kashi M; Wang Y; Rezvani Alanagh H; Farhadi Sabet Z; Li F; Cheng K; Li C; Qi Y; Nie G; Ying Z
    Adv Healthc Mater; 2021 Jun; 10(12):e2100051. PubMed ID: 34021735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
    Wang S; Zhou X; Zeng Z; Sui M; Chen L; Feng C; Huang C; Yang Q; Ji M; Hou P
    J Nanobiotechnology; 2021 Oct; 19(1):302. PubMed ID: 34600560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.